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EndocytosisLv2 is a human factor that restricts infection of some HIV-2 viruses after entry into particular target cells. HIV-
2 MCR is highly susceptible to Lv2 whereas HIV-2 MCN is not. The block is after reverse transcription but prior
to nuclear entry. The viral determinants for this restriction have been mapped to the HIV-2 envelope and the
capsid genes.
Our model of Lv2 restriction suggests that the route taken into a cell is important in determining whether a
productive infection occurs. Here we characterised the infectious routes used by MCN and MCR using
chemical compounds and molecular techniques to distinguish between potential pathways.
Our results suggest that susceptible MCR can enter restrictive HeLaCD4 cells via two pathways; a clathrin/AP2
mediated endocytic route that is sensitive to Lv2 restriction and an alternative, non-clathrin mediated route,
which results in more efﬁcient infection.. Harrison),
l rights reserved.© 2011 Elsevier Inc. All rights reserved.Introduction
A number of innate immune mechanisms aimed at preventing
retroviral infection have been described (Goff, 2004; Han et al., 2008;
Holmes et al., 2007; Nisole et al., 2005; Yan and Kozak, 2008; Zhou
et al., 2009). We have identiﬁed a post-entry restriction to HIV-2
viruses termed Lv2 (McKnight et al., 2001). This restriction was
originally described with the primary isolate prCBL 23 and the T-cell
line adapted variant CBL-23. Whereas both viruses replicate with the
same efﬁciency on some cell lines, such as CD4 expressing C8166, NP2
and U87, the primary virus is less efﬁcient at replicating in CD4
expressing HeLa and GHOST/HOS cell lines (McKnight et al., 2001).
Molecular clones of the restricted prCBL-23 and non-restricted CBL-23
were generated, termed MCR and MCN respectively (Schmitz et al.,
2004). Analysis of reverse transcripts produced byMCR andMCN after
challenge of restrictive cells indicated that, although equal levels of
reverse transcripts were eventually produced for both viruses, reverse
transcription is delayed for MCR (Marchant et al., 2005; Schmitz et al.,
2004). Pseudotyping restrictive core with VSV-G Env overcomes Lv2
restriction (McKnight et al., 2001; Schmitz et al., 2004). A single
amino acid substitution in Envelope (Env) at position 74 from
glutamic acid (E) to glycine (G) confers the non-restricted phenotype
onto a previously restricted particle. In Gag, a restricted particle
could be converted to a non-restricted phenotype by a valine (V) to
isoleucine (I) change at position 207 (Reuter et al., 2005; Schmitzet al., 2004). Thus there is a role for both the Env and capsid (CA) for
Lv2.
To explain the above scenarioweproposed amodel inwhich the Env
determines the route taken into the cell and thus determines the
compartment intowhich the virus is delivered for subsequentuncoating
and reverse transcription.Oncedelivered, residue207 inCA is important
for either core stability or interactions with host factors (Schmitz et al.,
2004). A similar model has been proposed for the simian cell restriction
(Lv3), which is determined by the viral core and Env, as well as the
coreceptor (Chackerian et al., 1997; Pineda et al., 2007).
To investigate this model, drugs which affect endocytosis were
used to alter the route of entry of restricted viruses into cells. No
effects were seenwith the vacuolar H+ inhibitor Baﬁlomycin A1 (BFA)
which prevents organelle acidiﬁcation. However the use of com-
pounds like hypertonic sucrose and high concentrations of ammoni-
um chloride rescued infection of MCR on HeLaCD4 cells (Marchant
et al., 2005; Reuter et al., 2005). Expression of dominant negative
dynamin in the ghost cells was also shown to result in a modest
increase in infection of particles pseudotyped with the restricted
Env35 (Reuter et al., 2005).
A requirement for membrane cholesterol and possibly lipid rafts
was identiﬁed using methyl-beta-cyclodextrin (MBCD). Removal of
membrane cholesterol rescued infection by the restricted MCR virus
but had no effect on MCN infection on HeLaCD4 cells (Marchant et al.,
2005). Truncation of the virus receptor CD4 cytoplasmic tail, which is
essential for receptor mediated endocytosis andmaintenance of lipid-
raft domain interactions (Marchant et al., 2005; Pitcher et al., 1999)
rescued MCR but had no effect on MCN or on infection of non-
restrictive cell lines (Marchant et al., 2005).
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Fig. 1. Actin disruption enhances MCR pseudotyped virus infectivity on restricted
HeLaCD4 cells. (A) Effect of drugs acting on actin or microtubule stability. Infection of
VSV-G Env pseudotyped RodA GFP particles were compared on cells treated with
DMSO, Cytochalasin D (Cyt-D), Latrunculin B (Lat-B), Jasplakinolide (Jas) and
Nocodazole (Noc). The percentage infection is shown (%Transduction) on the Y-axis.
(B) As in A, except infectedwithMCN andMCR pseudotyped particles. (C) Time course of
Cyt-D addition. Cyt-D was added to cells for 2 hours at a point either 2 hours prior to
infection (−2), at infection (0) or after infection (+2). Foci forming units perml (FFU/ml)
are shown for MCR delta Env particles pseudotyped with MCR, error bars represent the
standard deviation of the mean.
48 I.P. Harrison, Á. McKnight / Virology 415 (2011) 47–55Together these experiments supported the model that infection of
restricted cell types by particles carrying the restricted Env might be
via a pH-independent endocytic pathway. An alternative model, not
yet fully excluded, is that restricted viruses may fuse at the plasma
membrane (PM) but through different microdomains. The fate or
route taken by a virus that fuses through a lipid raft might be very
different from that taken by a virus fusing in a non-raft domain (Del
Real et al., 2002). However, the use of high concentrations of reagents
like MBCD may adversely affect the structure of the PM also affecting
endocytosis (Quirin et al., 2008).
The actin cytoskeleton may be either an impediment or an aid to
the early stages of HIV infection (Marsh and Bron, 1997). Cortical actin
forms a layer just under the PM and endocytosis could bypass this
barrier. The HIV Nef protein and coﬁlin activation by coreceptor
signalling have been implicated in overcoming the actin cortex in
various cell types (Campbell et al., 2004; Chazal et al., 2001; Yoder
et al., 2008). Then again, reverse transcription complexes (RTC)
associate with the actin cytoskeleton and this association is required
for the initiation of reverse transcription (Bukrinskaya et al., 1998).
Finally, actin itself has been implicated with certain endocytic routes
into the cell.
Here we investigated if there is a role for the actin cytoskeleton in
Lv2 restriction. We show that MCR infection on the restricted cell line
is enhanced by actin disruption but not on permissive NP2CD4/CXCR4
cells or with the non-restricted MCN virus on either cell type. We
further show thatMCR can enter HeLaCD4 cells viamultiple routes, one
of which is clathrin mediated endocytosis (CME) as it is dependent on
clathrin, AP2 and actin. This route is sensitive to the Lv2 so prevention
of CME directs viruses through the alternative pathway where
infection is more successful.
Results
Effect of actin disruption on MCR infection ofHeLaCD4 cells
We ﬁrst determined whether disruption of the actin network
would effect the infection of pseudotyped virus particles. HIV-2 RodA
GFP particles, pseudotyped with VSV-G or HIV-2 Env (MCN or MCR),
were produced and standardised on NP2CD4/CXCR4 cells. RodA capsid
has the restrictive amino acid (valine) at position 207 and was shown
to have the restrictive phenotype (Supplementary Fig 1). HeLaCD4 and
NP2CD4/CXCR4 cells were treated for 2 hours with drugs to disrupt the
actin cytoskeleton (Cyt-D, Lat-B and Jas) or microtubule network
(Noc). Cells were then challenged with peudotyped virus for 2 hours
in the presence of drugs. FITC-phalloidin treated cells show that
within 2 hours of Cyt-D or Lat-B exposure the actin cytoskeleton has
completely collapsed on both cell types (data not shown). The relative
infectivity for each virus compared to the DMSO control is shown
(Fig. 1). The short treatment with drugs affecting the actin or
microtubule network had little effect on the level of infection of
VSV-G pseudotyped RodA GFP particles (A). In contrast, inhibition of
actin polymerisation by Cyt-D and Lat-B resulted in enhancement of
infection of MCR pseudotyped particles by approximately 6-fold on
HeLaCD4cells. Stabilisation of polymerised ﬁlaments with Jas also
resulted in an increase in MCR particle infection (Fig. 1B). This
infectivity enhancement is greatest for MCR Env on HeLaCD4cells; a
maximum of a 2-fold enhancement was produced for MCR pseudo-
typed particles on the non-restricted NP2CD4/CXCR4 cell line or with
MCN pseudotyped particles on either cell type. Actin disruption by
inhibition of polymerisation (Cyt-D and Lat-B) and stabilisation of
actin ﬁlaments (Jas) both result in enhanced MCR infection on
HeLaCD4 cells. This suggests that dynamic actin turnover is required
for restricted infection of MCR on HeLaCD4 cells.
Themicrotubule network has been implicated as a requirement for
transport of RTCs towards the nucleus (Bukrinskaya et al., 1998;
Komano et al., 2004; McDonald et al., 2002; Taunton, 2001). In oursystem, treatmentwith nocodazole for only 2 hours had little effect on
any of the viruses (Fig. 1A and B).
A time course of drug treatment followed by virus challenge was
used to determine whether the effect of Cyt-D treatment was early or
late in viral entry (Fig. 1C). Cells were treated with Cyt-D for either;
2 hours prior to, at the same time or 2-hour post viral challenge. Cells
were challenged with MCR pseudotyped particles and the amount of
infection was compared to the DMSO alone controls. A 7.5-fold and 5-
fold enhancement in infection was produced when cells were treated
2 hours prior to or at the same time as viral challenge. At 2 hours post
infection, Cyt-D treatment only produced a 2-fold enhancement in the
level of infection. This suggests that the effect of actin disruption
occurs early during infection of the Lv2 restricted MCR virus.
49I.P. Harrison, Á. McKnight / Virology 415 (2011) 47–55The above effects of Cyt-D, Lat B and Jas were seen with
pseudotyped viruses. Next we conﬁrmed that actin disruption had a
similar effect on full-length, replication competent viruses. The
infectious titre of HIV-2 molecular clones MCN, MCR and HIV-1
clone 89.6 was determined on HeLaCD4 and NP2CD4/CXCR4 cells treated
with actin disrupting drugs or DMSO controls (Fig. 2A). Fig. 2B is
calculated from Fig. 2A to give the Lv2 fold restriction (infectious titre
on non-restricted NP2CD4/CXCR4 cells over the restricted HeLaCD4 cells).
Similar to the results obtained with pseudotyped particles, infection
with the replication competent MCR virus was enhanced by
approximately 4-fold after actin disruption and by less than 2-fold
for MCN. No enhancement was seen for HIV-1 89.6 virus. Thus Cyt-D
treatment alone is sufﬁcient to rescue the Lv2 phenotype, while
causing no effect on MCN or HIV-1 viruses. This is partly as actin
disruption causes a reduction in NP2CD4/CXCR4titre (3-fold) as well as
increasing the level of infection on HeLaCD4 cells. It is still apparent
that actin disruption rescues a large proportion of the Lv2 phenotype,
possibly representing the Env component of the restriction.Enhanced infectivity after actin disruption maps to Lv2 Env determinants
The viral Env determinant for Lv2 has been identiﬁed as an amino
acid substitution at position 74 in Env and at position 207 in Gag
(Reuter et al., 2005; Schmitz et al., 2004). We investigated whether
the enhanced infectivity of MCR pseudotyped particles after actin
disruptionmapped to the same determinants (Fig. 3). First we studied
amino acid 74 in Env by using two Env expression constructs. Env35 is
an independent clone from the restricted virus prCBL-23 whereas 35–
74 is the same Env with the point mutation at position 74, to give the
non-restricted phenotype (Reuter et al., 2005). In addition to theseB 
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Fig. 2. Actin disruption enhances full-length MCR infectivity on restricted HeLaCD4 cells.
(A) Effect of actin disruption on full-length molecular clones. Infectious titres of HIV-2;
MCN and MCR or HIV-1 89.6 after DMSO or Cyt-D treatment. (B) Lv2 fold restriction
calculated from the titre of infection on NP2CD4/CXCR4/Titre on HeLaCD4 cells in the
presence and absence of Cyt-D (titres from A).Envs, MCN andMCRwere pseudotyped onto the restrictedMCR (delta
Env) particles. NP2CD4/CXCR4, HeLaCD4 and H399CD4 cells were
challenged with virus after prior treatment with DMSO or Cyt-D
(Fig. 3A). H399CD4 cells express CD4 with a cytoplasmic tail deletion
which reduces endocytosis and results in lack of localisation of this
receptor in lipid rafts (Marchant et al., 2005; Pitcher et al., 1999).
H399CD4 cells do not have the Lv2 restriction (Marchant et al., 2005).
There was no infectivity enhancement for any of the viruses on the
permissive NP2CD4/CXCR4 cells after Cyt-D treatment; indeed infections
were reduced by up to 80%. In contrast infection by both Lv2 sensitive
MCR and Env35 pseudotypes was enhanced by 7.5-fold and 4.5-fold
respectively on HeLaCD4 cells by actin disruption. In contrast a
maximum of 2-fold infectivity enhancement was seen on HeLaCD4
cells for the Lv2 insensitive MCN or Env35-74 pseudotyped particles.
We conﬁrmed that restricted HIV-2 viruses do not exhibit a restricted
phenotype on H399CD4 cells as MCN pseudotyped particles could
infect both HeLaCD4 and H399CD4 with equal efﬁciency whereas MCR
pseudotyped particles showed a greater than 6-fold increase in
infection on H399CD4 cells (Fig. 3A, see DMSO). Further to this, we
show that treatment with drugs to disrupt the actin cytoskeleton
caused only minor infectivity enhancement of the Lv2 restricted MCR
or Env35 pseudotyped particles on these cells(Fig. 3A). The data from
Fig. 3A are also shown as the relative infectivity compared to the
DMSO control as a useful method to depict the degree of infectivity
enhancement (Fig. 3B).
In addition to Env, the Lv2 restriction is determined by the viral core
(Schmitz et al., 2004), we therefore determined if different viral cores
are affected by actin disruption. Viral cores derived from the Lv2 non-
restricted MCN (MCN delta Env) were pseudotyped with VSV-G, MCN
and MCR Envs. NP2CD4/CXCR4 and HeLaCD4 cells were challenged with
standardised virus after treatmentwith DMSOor Cyt-D. Infection by the
control VSV-G pseudotyped particles is reduced by actin disruption on
both theHeLaCD4 andNP2CD4/CXCR4 cells (Fig. 3C). Again onHeLaCD4 cells,
infection by MCR pseudotyped particles is enhanced by 6-fold by actin
disruption whereas MCN pseudotyped particles are enhanced by less
than 2-fold. The effects were speciﬁc to the restrictive cell type as there
was no infectivity enhancement for any of the viruses on NP2CD4/CXCR4
cells after actin disruption. This indicates that actin disruption can
enhance the infectionofboth restrictedandnon-restricted viral cores on
HeLaCD4 cells when pseudotyped with the restrictive MCR Env.
We further probed the core dependency of Lv2 and tested whether
actin disruption on HeLaCD4 cells enhanced infectivity for an HIV-1
viral core pseudotyped with the restrictive MCR Env. HIV-1 (NL4.3
GFP) and HIV-2 (RodA GFP) viral particles were pseudotyped with
VSV-G, MCN and MCR Env(Fig. 3D). HeLaCD4 cells were challenged
with pseudoviruses after treatment with Cyt-D. Infection of the
control VSV-G pseudotyped particles was slightly reduced after Cyt-D
treatment for both HIV-1 and -2 cores. Infectivity of the HIV-1 and -2
cores was enhanced by only 2.2- and 1.7-fold when pseudotyped with
MCN Env. As we have already seen, infectivity of the HIV-2 RodA GFP
derived particles pseudotypedwithMCR Envwas enhanced by almost
5-fold. The same Env however on the HIV-1 core resulted in only 2.6-
fold infectivity enhancement. This suggests that infectivity enhance-
ment after actin disruption is greatest when MCR Env is pseudotyped
onto an HIV-2 rather than HIV-1 core.
In summary the viral determinants of Lv2 have previously been
mapped to point mutations in Env and CA. Here we see that actin
disruption (by stabilisation or destabilisation) in restrictive HeLaCD4
cells enhances infectivity in an Env-dependent manner and maps to
the amino acid at position 74. Infectivity enhancement can be seen
with both restricted MCR and non-restricted MCN cores but is less
obvious with HIV-1 derived cores. This agrees with the lack of
infectivity enhancement seen with either of the HIV-1 full-length
viruses tested. The modest enhancement of MCN pseudotyped
particle infection on HeLaCD4 cells after actin disruption agrees with
a weak restriction of MCN viruses.
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Fig. 3. Enhancement of infection of MCR pseudotyped particles on HeLaCD4 cells maps to the viral Env. (A) NP2CD4/CXCR4, HeLaCD4 and H399CD4 cells were infected with MCR delta Env
particles pseudotyped with MCN, MCR, 35, 35–74 Env. FFU/ml in the presence of either DMSO or Cyt-D are shown for each cell line. (B) Relative infectivity in the presence of Cyt-D
compared to control DMSO infections. Calculated from A by dividing the FFU obtained with Cyt-D over that obtained in the presence of control DMSO. (C) MCN delta Env particles
pseudotyped withMCN,MCR or VSV-G Env were titrated onto NP2CD4/CXCR4 and HeLaCD4 cells in the presence of indicated drugs. (D)Modest enhancement of MCR Env on HIV-1 core.
MCN, MCR and VSV-G Env were pseudotyped onto HIV-2 RodA GFP or HIV-1 NL4.3 GFP particles. Percentage infection of HeLaCD4 cells in the presence of Cyt-D is shown as compared
to control DMSO treatment.
50 I.P. Harrison, Á. McKnight / Virology 415 (2011) 47–55Actin disruption rescues a large proportion of Lv2 restriction
MCN has amild (7-fold) restriction compared toMCR, which is 25-
fold restricted (Fig. 2A). The MCN restriction may reﬂect either basal
Lv2 or inherent differences with the infectability of the two cell lines.
It should be noted that H399CD4 cells are also 2- to 3-fold less
infectable than NP2CD4/CXCR4. TheMCR Env is almost 35-fold restricted
when pseudotyped onto either the restricted RodA core (Supplemen-
tary Fig 1B) or the non-restricted MCN core (data from Fig. 3C). MCN
Env is 8- to 9-fold restricted when pseudotyped onto the RodA core
(Supplementary Fig 1B) but only 2-fold restricted on the MCN core
(data from Fig. 3C), highlighting the dual Env and Core components of
Lv2 restriction.
After actin destabilisation, we observed a 6- to 9-fold enhance-
ment of MCR pseudotyped particle infection (irrespective of core) anda 2- to 4-fold enhancement of MCN pseudotyped infection. As even
non-restricted viruses show a fold restriction of 2- to 7-fold, we
believe that this represents the majority of the Lv2 restriction.
Role of cortical actin early in infection
TheMCR Envmight deliver viral cores into regions of the cell where
the cortical actin is especially dense and behaving as a barrier to
infection (Campbell et al., 2004; Marsh and Bron, 1997; Yoder et al.,
2008). Thus actin disruption might be aiding transition through this
cortical actin. Therefore, we focussed on drugs that disrupt the cortical
actin network which we hypothesised would have similar effects to
those that disrupt the actin cytoskeleton. Activated coﬁlin had been
reported to increase cortical actin depolarisation and remodelling
enabling theRTC tomove into the cell (Yoder et al., 2008). Staurosporine
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Fig. 4.MCR Env directs virus particles via a less productive route in HeLaCD4 cells that is
dependent on clathrin and AP2. Percent infection of NP2CD4/CXCR4and HeLaCD4 cells in
the presence of drugs affecting clathrin pathway acidiﬁcation and endocytosis;
baﬁlomycin A1 (BFA) and chlorpromazine. RodA GFP particles, pseudotyped with
MCN, MCR or VSV-G Env.
51I.P. Harrison, Á. McKnight / Virology 415 (2011) 47–55is a general serine/threonine kinase inhibitor which has been shown to
prevent the LIMK-1 mediated phosphorylation (inactivation) of coﬁlin,
therefore increasing the amount of activated coﬁlin in cells (Yoder et al.,
2008).
Initial experiments determined the range of concentrations of
Staurosporine that could be used to treat HeLaCD4 and NP2CD4/CXCR4
cells without cytotoxic affects. Cell viability studies showed that
concentrations up to but not beyond 50 nM were tolerated (not
shown). Levels of total coﬁlin and phosopho-coﬁlin in HeLaCD4 and
NP2CD4/CXCR4 cells treated with Staurosporine were determined by
Western blotting. Drug treatment effectively reduces the level of
inactive phospho-coﬁlin while not affecting the level of total Coﬁlin
(Supplementary Fig 2A).
HeLaCD4 and NP2CD4/CXCR4 cells were treated with Staurosporine
for 2 hours prior to, and during infection. Cells were infected with
RodA GFP particles pseudotyped with MCN, MCR and VSV-G Env, the
percentage infections are shown (Supplementary Fig 2B). Treatment
of HeLaCD4cells with Staurosporine did not cause an increase in
infection of VSV-G pseudotyped particles compared to the DMSO
treated cells. Infectivity of MCN and MCR pseudotyped particles was
increased on HeLaCD4 cells after Staurosporine treatment(2.7-fold and
4.4-fold, respectively). Staurosporine treatment therefore resulted in
minor enhancement of both MCR and MCN pseudotyped infection on
HeLaCD4 cells. No infectivity enhancement was seen on NP2CD4/CXCR4
cells with any of the viruses. Enhanced infectivity was detected with
NL4.3 pseudotyped HIV-1 cores on HeLaCD4 cells (2.3- to 3.3-fold, data
not shown), suggesting that enhanced infectivity was not speciﬁc for
MCR pseudotyped particles. We therefore believe that Lv2 restriction
is unlikely to result speciﬁcally from particles becoming trapped in the
cortical actin.
MCR Env directs infection via an endocytic pathway
CME has been shown to be dependent on the actin cytoskeleton
(Pelkmans et al., 2005; Robertson et al., 2009; Smythe and Ayscough,
2006). It is possible that particles pseudotyped with MCR Env take a
CME route into cells that result in Lv2 restriction. By disrupting the
actin cytoskeleton, we may have bypassed this CME route and
therefore increased the virus infectivity. The role of CME was studied
using BFA to inhibit endosome acidiﬁcation and chlorpromazine to
inhibit AP2 recycling. HeLaCD4 and NP2CD4/CXCR4 cells were infected in
the presence of these speciﬁc inhibitors by RodA GFP particles
pseudotyped with MCN, MCR or VSV-G Env. The VSV-G Env directs
virus particles through the CME pathway. Infection by VSV-G
pseudotyped particles was greatly reduced by the presence of BFA
on both cell lines, demonstrating that endosome acidiﬁcation was
inhibited (Fig. 4). We saw no effect of chlorpromazine on VSV-G
pseudovirus infection in contrast to previous reports using wild type
VSV (Johannsdottir et al., 2009).Infection of MCR pseudotyped
particles were not enhanced on HeLaCD4 cells treated with BFA. This
conﬁrms previous observations (Marchant et al., 2005) and suggests
that lysosomal degradation cannot account for Lv2 restriction.
Strikingly, inhibition of AP2 recycling by chlorpromazine treatment
of HeLaCD4 cells resulted in a 6.4-fold increase in infectivity of MCR.
This increase was greater than the 1.5-fold increase seen on the
permissive NP2CD4/CXCR4 cell line. Infection by MCN pseudotyped
particles was not enhanced by treatment with either of the
compounds, indeed treated NP2CD4/CXCR4 cells showed reduced levels
of infection compared to the control (Fig. 4).The observation suggests
that susceptibility of MCR pseudotyped particles is dependent on AP2
recycling.
Clathrin and AP2 are required for the restrictive entry pathway
A previous study showed that chlorpromazine treatment results in
destabilisation of membranes facilitating viral fusion albeit at muchhigher concentrations (10-fold) used here (Jeetendra et al., 2002).
Another possibility for the action of chlorpromazine that cannot be
excluded from the above experiments is that that the effect is due to
actin remodelling via the action of chlorpromazine on phospholipase
C/protein kinase C (Dwivedi and Pandey, 1999; Larsson, 2006; Milzani
and DalleDonne, 1999; Uratsuji et al., 1985; Wrenn et al., 1981).
To probe further the requirement for AP2 we used siRNA to dissect
the pathways used by pseudotyped particles for entry into HeLaCD4
cells. Fig. 5A shows Western blots against clathrin heavy chain (CHC),
clathrin light chain (CLC) Hip1R, AP2 mu 1 and control tubulin
samples showing speciﬁc knockdown of protein expression after
siRNA treatment. HeLaCD4 cells, treated with speciﬁc siRNA, were
infected with MCN, MCR or VSV-G pseudotyped RodA GFP particles,
the percentage infection is shown. Infection by the control VSV-G
pseudotyped virus, which uses a clathrin-dependent route of entry, is
reduced by siRNA knockdown of clathrin heavy chains and HIP1R
(Fig. 5B). As previously described, knockdown of AP2 increased
infection of particles pseudotyped with VSV-G by almost 2-fold
(Johannsdottir et al., 2009). Infection by MCR pseudotyped particles
was increased following knockdown of CHC, CLC and AP2 mu 1 by up
9-fold. Since blocking components essential for CME increased the
level of infection, we hypothesise that CME of MCR pseudotyped
particles in HeLaCD4 cells leads to Lv2 restriction. Infection by MCN
pseudotyped particles was also enhanced by siRNA knockdown of
CHC, CLC and AP2 mu 1, but to a lesser extent than for MCR
pseudotyped viruses (between 2- and 4-fold enhancement) in line
with the observed weak restriction of MCN.
Macropinocytosis is also an entry pathway which is dependent on
actin (Marsh and Helenius, 2006). We used a speciﬁc inhibitor of
macropinocytosis, amiloride (Marechal et al., 2001), to investigate
whether this is a non-productive pathway used by MCR pseudotyped
particles. No differences in the level of infectivity for any of the viruses
were detected after amiloride treatment (data not shown).
From these results it appears that MCR Env mediates infection
through CME to enter HeLaCD4 cells leading to Lv2 restriction. A new
clathrin-dependent pathway has recently been described (Saffarian
et al., 2009) whereby endocytosis can occur through clathrin plaques.
This pathway is dependent on the protein Hip1R. We investigated
whether MCR Env directs endocytosis through a Hip1R-dependent
route by using speciﬁc siRNA against the protein. We found that there
was no effect of Hip1R knockdown for eitherMCN orMCR pseudotyped
Fig. 5. siRNA knockdown of components of the clathrin mediated endocytic pathway
enhance MCR pseudotyped virus infection on HeLaCD4 cells. HeLaCD4 cells treated with
scrambled siRNA or oligo's against; AP2 mu 1, Hip1R, clathrin heavy chain (CHC) or
clathrin light chain a and b (CLC). (A) Western blot of siRNA treated cells showing
reduction in speciﬁc proteins. (B) Treated cells were infected with MCN, MCR or VSV-G
pseudotyped viruses, percent infection is shown.
52 I.P. Harrison, Á. McKnight / Virology 415 (2011) 47–55viruses (Fig. 5B). Interestingly, infection by VSV-G pseudotyped viruses
was reduced 2.75-fold by Hip1R knockdown suggesting that this
pathwaymay be important for VSV-G infection ofHeLaCD4 cells (Fig. 5B).
Inhibition of proteasomal degradation does not relieve the restriction
Our results suggest that MCR pseudotypes enter HeLaCD4 cells via a
CME route which leads to Lv2. When entry through this route is
blocked, an alternative route is used that can result in productive
infection. We have also seen that treatment with BFA does not
appreciably rescue MCR Env mediated infection indicating that the
CME does not lead to lysosomal degradation (Fig. 4). We sought to see
if there was a role played by proteasomal degradation in Lv2
restriction. MG132, calpain, proteasome inhibitor I as well as a control
inhibitor of cysteine proteases (E-64) was used to study the role of
proteasomal degradation. RodA GFP particles pseudotyped with MCN,
MCR or VSV-G Env and were used to challenge restrictive HeLaCD4
cells in the presence of the proteasomal inhibitors. As has previously
been described (Wei et al., 2005) the use of these proteasomal
inhibitors resulted in a modest increase in infectivity for all the tested
viruses (Supplementary Fig 3). Infection of both MCN and VSV-G
pseudotyped particles was enhanced by a maximum of 1.8-fold after
treatment with proteasomaI inhibitor I. MCR pseudotyped particles
were enhanced by between 1.3- and 2.9-fold by treatment with
proteasomal inhibitors. As the enhancement of MCR infection did not
reach the level achieved by treatment with chlorpromazine or speciﬁc
knockdown of CME components, we suggest that the Lv2 active CME
route into HeLaCD4 cells does not rely on proteasomal degradation.
Discussion
We previously postulated that susceptibility of some HIV-2 viruses
to Lv2, a post entry restriction present in some human cells, wasdependent on the route of viral entry. Here we show that an HIV-2
virus, MCR, previously shown to be Lv2 sensitive, enter restrictive
HeLaCD4 cells via at least two Env determined routes. One is an Lv2
restrictive route of entry and is dependent on intact actin, AP2 and
clathrin. The alternative route is not Lv2 restrictive. The results here
indicate that the pathway leading to Lv2 restriction is dependent on
entry of restricted virus through clathrin mediated endocytosis, is
dependent on actin stability and is not degraded in lysosomes.
Furthermore our data indicate that CME by MCR Env and VSV-G Env
differ in their adapter requirements.
We initially observed that infection of restrictedMCR pseudotyped
viruses on the restrictive HeLaCD4 cell line was markedly enhanced
upon actin disruption in an Lv2 manner. Thus delivery to Lv2
restriction is at least partially dependent on the actin cytoskeleton
as its disruption causes an increase in infection. We looked at further
possible mechanisms of restriction that might involve actin stability.
Cortical actin has also been shown to form a barrier that the RTC needs
to overcome (Campbell et al., 2004; Yoder et al., 2008). Treatment of
cells with drugs that disrupt the cortical actin network resulted in a
modest enhancement to both MCN andMCR infection of HeLaCD4 cells
but not VSV-G mediated infection. VSV-G pseudotyped particles are
endocytosed deep into cells, only exiting from late endosomes,
therefore avoiding the cortical actin layer. Staurosporine treatment
would not be expected to affect infection of VSV-G pseudotyped
particles, in agreement with our data. Staurosporine treatment
resulted in a modest enhancement of infection for MCN and MCR
pseudotyped HIV-2 and HIV-1 particles. As treatment did not
selectively rescue MCR infection it is unlikely that cortical actin itself
is responsible for Lv2 restriction. However, the modest enhancement
in MCN and MCR mediated infection of HeLaCD4 cells indicates that
either cortical actin or actin reorganisation has a role in early infection
of HIV-2. This enhancement may reﬂect infection by particles using a
route of infection involving direct fusion at the plasma membrane.
The actin cytoskeleton is also required for endocytosis (Boucrot et al.,
2006; Cureton et al., 2009; Robertson et al., 2009). We previously
reported that treatment of restricted HeLaCD4 cells with hypertonic
sucrose solution rescues Lv2 (Marchant et al., 2005). This treatment
inhibits all the major endocytic routes including CME (Ivanov, 2008).
AP2 is an adaptor for CMEandwe found that inhibition of AP2 recycling,
by chlorpromazine treatment, caused a marked increase in infection
supporting our previous notion thatMCR Env directs viral particles into
HeLaCD4 cells via an endocytic route. Furthermore, depletion of CHC and
CLC as well as AP2 mu 1 by speciﬁc siRNA also enhanced MCR particle
infection by up to 9-fold on HeLaCD4 cells. Thus actin disruption on
HeLaCD4 cells results in the inhibition of the non-productive CME
pathway, forcing theMCRpseudotyped virus touse analternative route.
In contrast, infection by non-restrictive MCN pseudotyped particles is
less dependent on AP2 or clathrin; no infectivity enhancement was
produced after chlorpromazine treatment and only a 2- to 4-fold
enhancement was produced after speciﬁc siRNA knockdown of CME
components, possibly representing a weak susceptibility to Lv2.We
cannot as yet rule out that non-restricted viruses such as MCN use the
same route are not sensitive to Lv2.
Ourmodel that endocytosis leads to Lv2 restriction is supported by
the observation that the level of reverse transcripts produced by MCR
pseudotyped particles reaches the same level, but is delayed
compared to MCN (Marchant et al., 2005; Schmitz et al., 2004). As
reverse transcription is not initiated until the viral core is released into
the cytoplasm (Bukrinskaya et al., 1998) the delay could be explained
as the core is contained within an endosome and is released later as
the endosome travels ﬁrst through the cytoplasm.
Preventing endosome acidiﬁcation has been shown to enhance the
level of infection for certain HIV-1 isolates like SF2 (Schwartz et al.,
1998; Wei et al., 2005) indicating that HIV can survive entry through
endocytic pathways if they can be protected from degradation. We
examined whether endosome acidiﬁcation might be a factor in Lv2
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pseudotype particle infection. The lack of signiﬁcant rescue of the Lv2
phenotype by preventing endosome acidiﬁcation supports the model
that Lv2 restriction does not result from the degradation of virions in
lysosomes. Proteasomal inhibitors resulted in a modest enhancement
of MCN, MCR and VSV-G pseudotyped particles on HeLaCD4 cells. The
lack of selective rescue of the Lv2 sensitive MCR suggests that Lv2
restriction does not involve the proteasome. Therefore it appears that
neither lysosomal nor proteasomal degradation is involved in the Lv2
phenotype.
We may speculate, in the absence of evidence to the contrary, that
the alternative pathway used by MCR pseudotyped particles may be
the same route used by MCN and that this route could be by direct
fusion. A small level of enhancement can be seen on MCN infection
after actin disruption or siRNA treatment. This could indicate that
either the alternative pathway has some requirement for actin and
AP2 or that MCN does not exclusively use the alternative pathway.
Based on previous work involving MCR/MCN chimeras we favour the
second hypothesis that neither MCR nor MCN exclusively uses a
speciﬁc pathway but instead has a preference for either the actin-
dependent or -independent route in HeLaCD4 cells.
Interestingly, VSV-G also uses a CME pathway to enter cells
(Cureton et al., 2009; Johannsdottir et al., 2009; Sun et al., 2005) yet
rescues MCR core from Lv2. Thus there are fundamental differences in
the path of core delivery by the VSV-G compared to that of MCR Env.
For instance MCR is dependent on the AP2 adaptor to infect via CME
whereas VSV-G infection, at least in HeLaCD4 cells, is independent of
AP2 (Johannsdottir et al., 2009). Since the CME used by VSV-G and
MCR differ in the adaptors they require, it is likely that endosomal
trafﬁcking is also a critical factor leading to Lv2. We have excluded use
of a novel CME pathway described in which clathrin plaques are
endocytosed in an Hip1R-dependent manner distinguishing them
from conventional clathrin coated vesicles (Poupon et al., 2008). The
plaques are internalised from the basolateral surface of speciﬁc cells,
including HeLaCD4. No enhanced infectivity of MCR pseudotyped
particles was seen when we used siRNA against Hip1R a protein on
which this pathway depends. Intriguingly infection by VSV-G
pseudotyped particles was decreased by more than 2.5-fold suggest-
ing the Hip1R route may be used for VSV-G mediated virus entry.
We further conﬁrmed that the Env determinant for Lv2, previously
mapped amino acid 74 (Reuter et al., 2005), is responsible for the
affects seen by actin disruption and CMEmediated Lv2 restriction. We
compared MCR pseudotyped particles produced with the restricted
and non-restricted core and showed that infection was enhanced for
both after actin disruption on HeLaCD4 cells. Interestingly, HIV-1
pseudotyped with MCR Env could also be rescued, but to a lesser
extent than MCR or MCN. Thus rescue of virus infection on HeLaCD4
cells after actin disruption is primarily dependent on the Env and to a
lesser degree on core.
Our studies indicate that CME is not used for MCR entry of
NP2CD4/CXCR4 (permissive) cells suggesting that the MCR virus uses
different routes depending on the target cell. Virus use of alternative
infectious pathways in different cell types is not unprecedented. VSV-G
entry into HeLaCD4 cells is independent of the AP2 (Johannsdottir et al.,
2009) but is AP2 dependent on entry into Mink (Mu-lv-1) and African
Green Monkey (BSC-1) cells (Cureton et al., 2009; Sun et al., 2005).
Ecotropicmurine leukaemia virushas alsobeen shown to enterdifferent
cell types by various mechanisms (Kizhatil and Albritton, 1997).
The use of endocytosis as an infectious pathway for HIV has been a
controversial area, reviewed in Permanyer et al. (2010), however a
role for endocytosis for cell free virus (Daecke et al., 2005; Miyauchi
et al., 2009) and for transport from virological synapses (Hubner et al.,
2009) has been described. Here we show that the infection via a CME
route can be non-productive as it leads to Lv2 restriction, raising the
possibility that Lv2 is part of a wider innate immunity targeted to
endocytosed cargo.Conclusions
This report supports our model for Lv2 restriction and expands on
the detail. We have seen that the restricted MCR virus can enter
restrictive HeLaCD4 cells via multiple routes; the route is determined
primarily by the Env. One route, classed as CME, is dependent on actin,
AP2 and clathrin and is relatively unsuccessful in mediating infection.
The alternative route is more successful for the virus because
diverting virus away from the clathrin-dependent route results in
an overall increase in infectivity.
Materials and methods
Cells
HeLaCD4, HeLa-H399CD4 (H399CD4), NP2CD4/CXCR4 and HEK 293 T
cells have previously been described (Pitcher et al., 1999; Schmitz
et al., 2004). Cells were passaged in Dulbecco's modiﬁed Eagle's
medium (Invitrogen), 10% Fetal Calf Serum (Biosera) and 1% penicillin/
streptomycin. HeLaCD4, H399CD4 and NP2CD4/CXCR4 cells were supple-
mented with 1 mg/ml geneticin (Melford Laboratories). Additionally,
NP2CD4/CXCR4 cells were cultured in the presence of 1 μg/ml puromycin
(PAA).
Plasmids and viruses
Virus stocks were prepared from infectious full-length and
chimeric HIV clones by polyethylenimine (Polysciences) transfection
of HEK 293 T cells. Brieﬂy, 10 cm2 tissue culture dishes were seeded
with HEK 293 T cells 24 hours prior to transfection. 6 μg of each
plasmid was mixed into 900 μl serum-free DMEM (Invitrogen)
containing 60 μl PEI (1 mg/ml). DNA solutions were incubated for
10 min at room temperature and added drop-wise to the cells. Cells
were washed once with DMEM after 6 hours. Viral supernatants were
harvested after 48 hours.
Infectious molecular clones for MCN, MCR, 89.6 and NL4.3 were
obtained from the AIDS reagent program or have previously been
described (Schmitz et al., 2004). Chimeric viruses consist of cores
pseudotyped with various envelopes. Core expressing plasmids RodA
GFP,MCNΔEnv orMCRΔEnv have previously been described (Marchant
et al., 2005; Reuter et al., 2005; Schmitz et al., 2004). Envelopes were
expressed from plasmids; VSV-G (pczVSV-G), MCN Env, MCR Env, 35
Env and 35–74 Env(Cannon et al., 1996; Marchant et al., 2005; Reuter
et al., 2005; Schmitz et al., 2004; Soneoka et al., 1995).
Infectivity assays
NP2CD4/CXCR4 and HeLaCD4 cells were seeded in 48-well trays at
1.8×104 cells/well in 200 μl of DMEM. The following day, where
applicable, cells were pre-treated with drug containingmedia or DMSO
controls. After 2 hours, 8000–20,000 FFUof virus (titredonNP2CD4/CXCR4
cells) was added in the presence of drug in a total volume of 100 μl for a
further 2 hours. Cells were thenwashed and infectivitywas determined
48–72 hours later by FACS or in situ immunostaining for p24 antigen.
GFP positive samples were analysed by ﬂow cytometry after
ﬁxation in 3.7% formaldehyde on a LSR II (BD Biosystems). Infected
cells were ﬁxed with cold (−20 °C) methanol:acetone (1:1), washed
with PBS then immunostained for p24 using mouse anti-HIV-1 p24
monoclonal antibodies EVA365 and 366 (NIBSC, UK) (diluted 1:50), as
previously described (Thomas et al., 2003). Infections are represented
as percentage of the DMSO control infection.
Compounds
Compounds were obtained from Sigma and diluted into DMSO
unless otherwise stated. Actin and microtubule disrupting compounds;
54 I.P. Harrison, Á. McKnight / Virology 415 (2011) 47–55cytochalasin D (Cyt-D, 3 μM), latrunculin B (Lat-B, 5 μM), jasplakinolide
(Jas, 125 nM) and nocodazole (Noc, 1 μM). Inhibitors of endocytosis;
baﬁlomycin (BFA, 10 nM) and chlorpromazine (Cpz, 10 ug/ml).
siRNA
Sixty picomoles of siRNA oligos (Qiagen) was mixed with 1.5 ul of
HiPerfect (Qiagen) and added to 1.8×104 HeLaCD4 cells in 48-well
plates, making a ﬁnal concentration of 200 nM. Three days later, cells
were infected or cell lysates were harvested for Western blotting. AP2
mu 1 (AP2 M1) (CGGCGAGAGGGTATCAAGTAT) Qiagen [SI03086300].
CHC (ATCCAATTCGAAGACCAAT) (Motley et al., 2003).Hip1R L-027079-
00 and Clathrin Light Chain; (a) D-004002-01, (b) D-004003-03
(Dharmacon).
Western blots
Total cell lysates from siRNA or Staurosporine treated cells were
probed with coﬁlin (1/2500, Cell Signalling), phospho-coﬁlin (1/2500
Cell Signalling), tubulin (1/2500, AbDSerotec), CHC (1/1000BD), CLC (1/
500 AbCam), AP2 mu 1 (1/2500, AbCam) and Hip1R (1/2500. AbCam)
antibodies. HRP-conjugated secondary antibodies against rat, mouse
and rabbitwereused at1/5000dilution. Proteinswerevisualisedusing a
chemiluminescence kit (ECL, Amersham Biosciences).
Supplementarymaterials related to this article can be found online
at doi:10.1016/j.virol.2011.04.001.
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